Drug Trial Radar · NCT07868835
Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
560
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Jul 2028
Study completion Aug 2028
Sponsor
- Lead sponsor
- Viking Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is one of two planned Phase 3 studies to support the weight management indication for VK2735 Oral in obese (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27kg/m2) adults with at least one weight-related comorbidity without type 2 diabetes mellitus.
Conditions
- Weight Loss
Interventions
VK2735Drug
VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily
Placebo comparatorDrug
Placebo comparator administered orally once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage change in body weight for participants receiving VK2735 orally once dailyTime frame: 68 weeks
Locations
20 sites in 1 country. Site status is shown where the registry gives one.
Viking Clinical Site #1020
Tucson, Arizona · Recruiting
Viking Clinical Site #1018
Chula Vista, California · Recruiting
Viking Clinical Site #1015
Lake Forest, California · Recruiting
Viking Clinical Site #1005
Melbourne, Florida · Recruiting
Viking Clinical Site #1003
The Villages, Florida · Recruiting
Viking Clinical Site #1013
Atlanta, Georgia · Recruiting
Viking Clinical Site #1001
Evansville, Indiana · Recruiting
Viking Clinical Site #1009
Valparaiso, Indiana · Recruiting
Viking Clinical Site #1014
Louisville, Kentucky · Recruiting
Viking Clinical Site #1004
Richfield, Minnesota · Recruiting
Viking Clinical Site #1029
Jackson, Mississippi · Recruiting
Viking Clinical Site #1028
Springfield, Missouri · Recruiting
Viking Clinical Site #1006
Rochester, New York · Recruiting
Viking Clinical Site #1035
Morehead City, North Carolina · Recruiting
Viking Clinical Site #1023
Medford, Oregon · Recruiting
Viking Clinical Site #1002
East Greenwich, Rhode Island · Recruiting
Viking Clinical Site #1030
Henderson, Tennessee · Recruiting
Viking Clinical Site #1031
Abilene, Texas · Recruiting
Viking Clinical Site #1026
Salt Lake City, Utah · Recruiting
Viking Clinical Site #1011
Seattle, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.